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Heparin is known to inhibit the binding of inositol 1,4,5-trisphosphate (Ins 1,4,5-P,) to high-affmity binding sites and 
to inhibit Ins 1,4,5-P,-induced Ca*+ release from intracellular membrane-bound stores [(1987) J. Biol. Chem. 262, 
12132-12136; (1987) FEBS L&t. 228, 57-591. We have performed studies to clarify the structural requirements for this 
action of heparin in rat liver microsomes. Both N- and O-linked sulphate groups contribute to binding activity, since 
de-N-sulphated heparin was without effect on the Ins 1,4,5-P, receptor whereas a polyxylan bearing only O-linked sul- 
phates (pentosan polysulphate) was as active as heparin. Therefore, the density of negative charge contributed by sulphate 
groups is important for the binding of heparin. Hepatitis with high and low affinity for antithrombin III both inhibited 
Ins 1,4,5-P, binding. There was a strong dependence on chain length, since binding activity decreased ramatically as 
the size of the heparin chain was reduced below that of 18-24 monosaccharide units. 
Heparin; Fragmin; Pentosan polysulfate; Inositol 1,4,5&sphosphate receptor; (Rat liver microsome) 
1. INTRODUCTION 
It is now widely recognised that a large variety of 
hormones, growth factors and other cell mediators 
use the breakdown of polyphosphoinositide(s) by 
an agonist-stimulated phospholipase C as the first 
step in their signal transduction pathway [3]. Both 
products of the breakdown of phosphatidylinositol 
4,Sbisphosphate (PtdIns 4,5-P2) are believed to 
play second messenger roles in cells. 1,2-sn- 
Diacylglycerol is known to activate protein kinase 
C in a Ca2+-stimulated and phospholipid- 
dependent manner [4] and Ins 1,4,5-PS causes the 
release of Ca2+ from an intracellular membrane- 
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bound store which is non-mitochondrial and may 
be the endoplasmic reticulum or a specialised 
region thereof [5]. 
Several tissues have been demonstrated to con- 
tain high-affinity binding sites for Ins 1,4,5-PS in- 
cluding adrenal cortex [6], cerebellum [7], 
neutrophils [8] and liver [8,9]. The relative order of 
potency of various inositol phosphates to displace 
Ins 1,4,5-P3 from these sites is strikingly similar to 
their ability to cause Ca2+ release from in- 
tracellular stores, suggesting that the binding sites 
mediate the Ca2+-releasing effects of Ins 1,4,5-P3 
[lo]. Heparin has been shown to inhibit binding of 
Ins 1,4,5-P3 to cerebellar membranes [l]. It will 
also inhibit Ins 1,4,5-Ps-induced Ca2+ release from 
rat liver microsomes [2] and is therefore acting as 
an Ins 1,4,5-P3 receptor antagonist. Recent studies 
have shown this mechanism of inhibition to be of 
a competitive nature [ 111. 
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Heparin is a heterogenous mixture of linear 
polysaccharide chains of varying lengths which can 
vary substantially in saccharide composition and 
degree of N-acetylation, 0- and N-sulphation 
depending on the source of the material [ 121. 
Therefore, it is of considerable interest to deter- 
mine what structural features of heparin confer on 
it the ability to act as an Ins 1,4,5-Ps antagonist. 
Here, we describe the effects of heparin and 
related substances on Ins 1,4,5-P3 binding and Ins 
1,4,5-Ps-induced Ca2+ release in a rat liver 
microsomal system. 
2. MATERIALS AND METHODS 
2.1. Microsome preparation 
Liver microsomes were prepared from overnight-starved 
adult male rats (Sprague-Dawley) by the method of Dawson 
and Irvine [13]. 
2.2. f’P/lns 1,4,5-P~binding assays 
Microsomal membranes (approx. 0.5 mg protein) were in- 
cubated for 30 min on ice in a total volume of 0.5 ml in a buffer 
with the following composition: 100 mM KCl, 25 mM 
NazHPOa, 20 mM NaCl, 1 mg/ml BSA, 0.5 mM EDTA at pH 
7.0 and containing “P-1abelled Ins 1,4,5-Ps (40-185 PM) and 
D-[2,d3H]mannose (for correction for trapped volume). In- 
cubations were started by the addition of microsomes to tubes 
containing radioligand and the substance of interest o be tested 
and were terminated by dilution with 5 ml of 0.25 M sucrose, 
10 mM KzHP04 (pH 7.0) followed by rapid filtration through 
pre-soaked Whatman GF/C filters using a vacuum apparatus. 
Two rapid 5-ml washes of the tube and filter were performed 
using the same buffer. The dilution, filtration and washing pro- 
cedure took lo-15 s. Filter-associated 32P and ‘H radioactivity 
was measured by dual-label iquid scintillation counting of the 
filters in 5.0 ml Atomlight scintillation fluid. Non-specific 
binding was defined as that remaining in the presence of added 
8.57 ,uM non-radioactive Ins 1,4,5-Ps and was subtracted from 
all binding results. 
2.3. Ins 1,4,5-Pj-induced Cd+-release measurement 
The release of Ca’+ from rat liver microsomes was measured 
using Ca*+ -selective lectrodes according to Dawson and Irvine 
[13]. Electrodes were manufactured using the Ca2’-selective 
ligand ETH 1001 [141. After uptake of Ca*+ by the microsomes 
to a steady-state l vel, GTP was added to give a final concentra- 
tion of 20 ,uM to enhance the effect of subsequent Ins 1,4,5-Ps 
addition [15]. When testing the effects of substances of interest 
these were added to microsomes 1 min prior to addition of 
0.5 pM Ins 1,4,5-Ps. We have found this to be the maximal con- 
centration for Ca2+ release in our hands. 
(4,5-‘*P)-labelled Ins 1,4,5-Ps (130 Ci/mmol) from New 
England Nuclear was used in preliminary binding studies but 
the majority of experiments utilised (5-32P)-labelled Ins 1,4,5-P3 
(1000 Ummol) obtained from Amersham International. There 
was no significant difference between results obtained with 
106 
radioligand from either source. D-[2,6-‘H]Mannose and 
unlabelled Ins 1,4,5-Ps were also obtained from Amersham. 
ETH 1001 was purchased from Fluka. Unfractionated heparin 
(from porcine intestinal mucosa, mean IU, 13000), de-N- 
sulphated heparin (mean M, 13 000) and pentosan polysulphate 
(Mr 1500-5000) were obtained from Sigma, and Fragmin (mean 
M, 5000) was purchased from Kabi-Vitrum. Heparin-derived 
oligosaccharides were prepared by a process of nitrous acid 
depolymerisation and repeated gel filtration [ 17-191. Fractions 
were designated high affinity (HA) or low affinity (LA) depen- 
ding on their behaviour on an antithrombin III affinity column 
as described in [20]. The numbers assigned to them signify the 
number of monosaccharide units in the chain. Thus, HA8 is an 
octasaccharide with high affinity for antithrombin III. 
3. RESULTS AND DISCUSSION 
We have previously demonstrated that the 
preparation of rat liver microsomes used in this 
study contains high-affinity binding sites which are 
probably the receptors through which Ins 1,4,5-P3 
causes Ca2+ release from intracellular stores [lo]. 
Fig.1 shows that Ins 1,4,5-[32P]P3 binding to this 
site can be prevented by unfractionated heparin 
and by Fragmin (a heterogenous low molecular 
mass heparin fraction with an average molecular 
mass of 5 kDa). Both polysaccharides exhibit 
similar affinity for the binding site, having EC50 
values of 4.8 and 8.0pg/ml, respectively. It can 
also be seen that de-N-sulphated heparin is ineffec- 
tive over the same range of concentrations as 
native heparin. Studies performed on smooth mus- 
cle cell microsomes have shown recently that de-N- 
sulphated heparin is unable to antagonise Ins 
Fig.1. Effect of heparin (A), de-N-sulphated heparin (A) and 
Fragmin (0) on [3ZP]Ins 1,4,5-Ps specific binding to rat liver 
microsomes. Means + SE from 3-4 independent experiments 
are shown. 
Volume 252, number 1,2 FEBS LETTERS July 1989 
1,4,5-P~induced Ca’+ release [ll]. We have con- 
firmed this finding in the rat liver microsomes used 
in the present study (not shown). This suggests that 
the sulphate groups in the heparin molecule play 
an important role in the interaction of heparin with 
Ins 1 ,4,5-PS receptor and raises the possibility that 
there may be a special role for N-sulphate groups. 
The synthetically 0-sulphated polyxylan pentosan 
polysulphate [21], is very effective at competing 
with Ins 1,4,5-[32P]P3 binding (fig.2), having an 
EC50 of 6.9 ,ug/ml. As pentosan polysulphate con- 
tains no N-linked sulphate groups [22], it is unlike- 
ly that the lack of effect of de-N-sulphated heparin 
on the Ins 1,4,5-P3 receptor is due to a specific lack 
of N-sulphate groups, but is more likely to be due 
to an overall reduction in density of sulphate 
groups compared to the parent heparin molecule. 
It should be noted that the removal of N-sulphate 
substituents will expose positively charged free 
amino groups. Fig.2 also shows that the ability of 
pentosan polysulphate to prevent Ins 1,4,5-P3 
binding is accompanied by inhibition of Ins 
1,4,5-P3-induced Ca2+ release. The concentration 
dependence for the displacement of Ins 
1 ,4,5-[32P]P3 binding by pentosan polysulphate is 
similar but not identical to that for inhibition of 
Ca2” release. This is probably due to the difference 
in conditions of buffer and temperature under 
which we measure Ca2+ release and binding. 
Unfractionated heparin consists of hetero- 
geneous polysaccharide chains of varying length 
Fig.2. Effect of pentosan polysulphate on [32P]Ins 1,4,5-Ps 
specific binding (B) and Ins 1,4,5-Ps-induced Ca*+ release (A) 
from rat liver microsomes. Data are means f SE from 4 
independent experiments (binding) or means rf: range from 2 
experiments (Ca’+ release). 
and we therefore sought to determine the activity 
of more well characterised oligosaccharides. 
Various oligosaccharide fractions of a narrow 
range in molecular size were separated into two 
classes by virtue of their affinity for immobilised 
antithrombin III [20]. The HA fractions contain 
the specific pentasaccharide sequence which is 
known to bind to antithrombin III whereas the LA 
fractions do not [ 17- 191. The results with HA and 
LA fractions were essentially similar and in both 
cases show a clear effect of chain length on the 
ability of the oligosaccharides to displace bound 
Ins 1,4,5-[32P]P3 from the microsomes. Fig.3 
shows the ability of each of the oligosaccharide 
fractions to compete with Ins 1 ,4,5-[32P]P3 for bin- 
ding to the microsomes at a saccharide concentra- 
tion of 20pg/ml. The ability of the HA18-24 
fraction to compete with labelled ligand is very 
similar to that of unfractionated heparin and 
Fragmin (which has a similar mean molecular mass 
to that of the purified HA oligosaccharide). 
However, the HA10-14 fraction has substantially 
lower activity and the HA8 fraction displays none 
--I- 
LAa 
In-21 
0 I LA20 In-31 HA la-24 (n=41 
Fig.3. Effect of heparin-derived oligosaccharide fractions 
(20/rg/ml) on [‘*PIIns 1,4,5-Pa specific binding to rat liver 
microsomes. Means f SE or f range (LA@ are shown. 
Number of independent experiments given in parentheses. HA, 
high affinity for antithrombin III; LA, low affinity for 
antithrombin III. Numbers indicate the number of 
monosaccharide units per oligosaccharide molecule. 
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at the concentration tested. Similarly, for the low- 
affinity fractions, LA20 had substantial displacing 
activity at 20 gg/ml whereas LA8 had essentially 
none. These results thus show a clear dependence 
of activity on chain length. All fractions which had 
significant displacement activity at that concentra- 
tion showed a concentration-dependent effect but 
the complete range of concentrations tested has 
not been shown for reasons of clarity. It was not 
possible to perform tests at concentrations higher 
than 20 pg/ml due to limitations in the amount of 
material available. 
We have shown here that the ability of heparin 
to act as an Ins 1,4,5-P3 receptor antagonist is 
dependent on the presence of sulphate groups and 
on molecular size. In addition, pentosan 
polysulphate, which is another linear polymer with 
a high degree of sulphation but different monomer 
composition, has been shown to act as an Ins 
1,4,5-P3 receptor antagonist. It is hoped that 
studies of this type will enable the design of low 
molecular mass compounds which may be specific 
Ins 1,4,5-P3 receptor antagonists. Such com- 
pounds would be invaluable experimental tools 
and may have therapeutic benefit in disease states. 
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